Acambis PLC - Total Voting Rights
RNS Number:9119IAcambis PLC30 November 2007Voting rights and capitalCambridge, UK and Cambridge, Massachusetts - 30 November 2007 - Acambis plc
("Acambis") (LSE: ACM), in conformity with the Financial Services Authority's
("FSA") Transparency Directive, notifies that on 30 November 2007 Acambis' sharecapital consisted of 107,759,461 ordinary 10p shares, each share having equalvoting rights.This figure may be used by shareholders as the denominator for the calculationsby which they will determine if they are required to notify their interest in,or a change to their interest in, Acambis under the FSA's Disclosure andTransparency Rules.
-ends-Enquiries:Acambis plcElizabeth Jones, Chief Financial OfficerLyndsay Wright, VP, Communications and IRTel: +44 (0) 1223 275 300About AcambisAcambis is a leading vaccine company developing novel vaccines that addresssignificant unmet medical needs or substantially improve standards of care.ChimeriVaxTM-JE, Acambis' most advanced product in its development-stagepipeline, has to date shown an excellent safety and efficacy profile followingpivotal Phase 3 trials. It is currently undergoing paediatric trials in Indiaand is partnered with Sanofi Pasteur and Bharat Biotech. Acambis' proprietaryChimeriVax(TM)technology, developed in association with St Louis University, hasalso been used to develop ChimeriVaxTM-West Nile, which is undergoing Phase 2clinical testing, making it the most advanced investigational vaccine againstthe West Nile virus. Acambis has established a global collaboration with SanofiPasteur for further development and commercialisation of the vaccine.ChimeriVax(TM)has also been applied to development of Sanofi Pasteur'stetravalent dengue vaccine, which has successfully demonstrated proof-of-conceptin a Phase 2 trial by generating 100% seroconversion to all four dengue virusserotypes.Acambis also has the only vaccine in development against Clostridium difficilebacteria, a leading cause of hospital-acquired infections. C. difficile isestimated to cause at least 350,000 cases of C. difficile-associated disease inthe US alone with annual costs to the healthcare system of $1.1bn. Acambis'influenza programme aims to develop a universal vaccine against influenza, forwhich a universal 'A' strain vaccine, ACAM-FLU-ATM, is currently being tested ina Phase 1 trial, and also includes various further vaccine candidates in theresearch and pre-clinical stages.Acambis is recognised internationally as the leading producer of smallpoxvaccines. Acambis' ACAM2000(TM)(Smallpox (Vaccinia) Vaccine, Live) vaccine foractive immunisation against smallpox disease for persons determined to be athigh risk for smallpox infection was licensed by the US Food and DrugAdministration in August 2007. Acambis has manufactured doses of ACAM2000(TM)foremergency-use stockpiles held by the US Government and several other governmentsaround the world. For safety and prescribing information, please refer towww.acambis.com/ACAM2000.Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and islisted on the London Stock Exchange (ACM). More information is available atwww.acambis.com."Safe Harbour" statementStatements contained within this news release may contain forward-lookingcomments, which involve risks and uncertainties that may cause actual results tovary from those contained in the forward-looking statements. In some cases, youcan identify such forward-looking statements by terminology such as 'may','will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes','estimates', 'predicts', 'potential', or 'continue'. Predictions andforward-looking references in this news release are subject to the satisfactoryprogress of research which is, by its very nature, unpredictable. Forwardprojections reflect management's best estimates based on information availableat the time of issue.
This information is provided by RNS
The company news service from the London Stock ExchangeENDTVRBMBITMMBJBMR
